Longeveron Inc. (LGVN)
- Previous Close
1.9200 - Open
1.9800 - Bid 1.4700 x 200
- Ask 2.3600 x 200
- Day's Range
1.8100 - 2.0600 - 52 Week Range
1.6200 - 44.0000 - Volume
482,621 - Avg. Volume
2,093,950 - Market Cap (intraday)
8.972M - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-10.2000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.05
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
longeveron.comRecent News: LGVN
Performance Overview: LGVN
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LGVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LGVN
Valuation Measures
Market Cap
8.92M
Enterprise Value
5.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.70
Price/Book (mrq)
1.32
Enterprise Value/Revenue
7.90
Enterprise Value/EBITDA
-0.28
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-66.49%
Return on Equity (ttm)
-157.19%
Revenue (ttm)
709k
Net Income Avi to Common (ttm)
-22.21M
Diluted EPS (ttm)
-10.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.36M
Total Debt/Equity (mrq)
30.28%
Levered Free Cash Flow (ttm)
-11.72M